Antiviral Medicines Center for Pandemic Readiness
Official title: Center for Antiviral Medicines & Pandemic Preparedness (CAMPP)
Funded at Scripps Research Institute, the · NIH-11542045 · Data updated 2026-11-12
A large NIH program aims to speed up discovery of oral antiviral drugs and other treatments to protect people from current and future deadly viruses like coronaviruses, flaviviruses, and hemorrhagic fever viruses.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Scripps Research Institute, the NIH-funded |
| Lab location | 1 site (La Jolla, United States) |
| Project start | May 16, 2022 |
| Project end | August 31, 2028 |
| Funding year | 2026 |
| Award (this year) | $16,901,726 |
| NIH project number | 4U19AI171443-02 |
| Project ID | NIH-11542045 on NIH RePORTER |
Who could benefit from this research
✓Could help
Not applicable to direct patient enrollment in this grant; the work is a center-wide research program developing antivirals that could benefit patients in the future.
✕Less likely to help
There is no immediate patient enrollment or direct therapy trial offered by this grant.
What this research studies
This center brings together experts to develop direct-acting antivirals and improve drug discovery pipelines for RNA viruses with pandemic potential. It focuses on coronaviruses such as SARS-CoV-2, SARS, and MERS, as well as Zika, West Nile, Dengue, Ebola, SFTS, and Lassa viruses, with attention to oral bioavailability and effective delivery. Researchers will work across multiple disciplines to identify antiviral candidates and move promising compounds toward usable therapies. The effort emphasizes preparedness so that safer, more accessible treatments could be available quickly in future outbreaks.
Why it matters
Potential benefit: If successful, patients could gain faster access to effective antiviral drugs and improved therapies during future outbreaks.
How similar studies have gone: Previous antiviral development efforts have improved options for some viruses, but there are still many viruses without approved treatments, making this an especially needed and ambitious effort.
Where this research is happening
-
Scripps Research Institute, the
La Jolla, United States Active
Researchers
- Principal investigator: Chanda, Sumit K — Scripps Research Institute, the
- Study coordinator: Chanda, Sumit K
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.